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Abstract
Background: Histamine is established as a potent inflammatory mediator and it is known to increased endothelial
permeability by promoting gap formation between endothelial cells. Previous studies have shown that aqueous
extract of Bixa orellana leaves (AEBO) exhibits antihistamine activity in vivo, yet the mechanism of its action on
endothelial barrier function remains unclear. Therefore, the current study aimed to determine the protective effect
of AEBO against histamine-induced hyperpermeability in vitro.
Methods: The endothelial protective effect of AEBO was assess using an in vitro vascular permeability assay kit.
Human umbilical vein endothelial cells (HUVEC) were used in the current study. HUVEC were pre-treated with AEBO
for 12 h before histamine induction. Vascular permeability was evaluated by the amount of FITC-dextran leakage
into the lower chamber. In order to elucidate the mechanism of action of AEBO, phospholipase C (PLC) activity,
intracellular calcium level, nitric oxide (NO) concentration, cyclic guanosine monophosphate (cGMP) production and
protein kinase C (PKC) activity were determined following histamine challenge.
Results: Histamine-induced increased HUVEC permeability was significantly attenuated by pretreatment with AEBO
in a time- and concentration-dependent manner. Upregulation of PLC activity caused by histamine in HUVEC was
suppressed by pretreatment with AEBO. Pretreatment with AEBO also blocked the production of intracellular
calcium induced by histamine in HUVEC. In addition, AEBO suppressed the NO-cGMP signaling cascade when
HUVEC were challenged with histamine. Moreover, PKC activity was significantly abolished by pretreatment with
AEBO in HUVEC under histamine condition.
Conclusion: In conclusion, the present data suggest that AEBO could suppress histamine-induced increased
endothelial permeability and the activity may be closely related with the inhibition of the PLC-NO-cGMP signaling
pathway and PKC activity.
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Background
Vascular endothelium plays a critical role as a sophisti-
cated gate-keeper that regulates the passage of solutes,
macromolecules and circulating cells across the blood
vessel wall [1]. Thus, endothelial permeability is import-
ant for the maintenance of vascular integrity in either
homeostasis or disease. However, disintegration of endo-
thelial cell junctions will lead to increased endothelial
permeability and subsequently, the formation of edema.
Endothelial hyperpermeaility is a hallmark of many
severe disorders, such as ischemic acute renal failure [2]
and sepsis [3]. Various factors contribute to endothelial
hyperpermeability, for example, inflammatory mediators,
oxidants and cytokines.
Histamine, produced by mast cells and macrophages
[4], is a known potent inflammatory mediator. By bind-
ing to its H1 receptor on endothelial cells, histamine can
cause the formation of gaps between endothelial cells,
eventually leading to endothelial hyperpermeability [5].
These effects involve multiple signalling cascades, for
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instance the activation of protein kinase C [6], the gener-
ation of inositol trisphosphate and a rise in intracellular
Ca2+ [7]. In addition, histamine-stimulated endothelial
hyperpermeability also involves the nitric oxide—cyclic
guanosine monophosphate (NO-cGMP) signaling path-
way [8]. Despite active research, treatment for endothe-
lial dysfunction remains widely lacking; this opens an
interest among researchers to explore new therapeutic
options for the prevention of endothelial leakage.
Bixa orellana, also known as “annatto”, is famous for
its colorant properties as well as its medicinal value.
Apart from antioxidant, antibacterial, analgesic [9], antil-
eishmanial and antifungal activities [10], leaves of B.
orellana have also been documented to have anti-
inflammatory activity [11]. Previous studies have also
shown that aqueous extracts of B. orellana leaves pos-
sessed antihistamine activity [12], and more recently,
Yoke Keong and colleagues (2013) have demonstrated
that B. orellana leaves are capable of suppressing endo-
thelial hyperpermeability stimulated by serotonin in vivo
[13]. However, the mechanism of action of B. orellana
leaf extract remains unclear. Therefore, the aim of this
study was to explore the protective effect of B. orellana
against histamine-induced hyperpermebility in human
umbilical vein endothelial cells (HUVEC). When a posi-
tive response was demonstrated, the effects of the
extract on signaling pathways that regulate endothelial
permeability were subsequently studied. Experimental
data suggested that AEBO protected the endothelial cell
barrier against histamine disruption by suppressing the
phospholipase C (PLC)–NO–cGMP signaling pathway.
Methods
Plant material
B. orellana leaves were collected from around Universiti
Putra Malaysia and their botanical identity was identi-
fied and confirmed by the Phytomedicinal Herbarium,
Institute of Biosciences, Universiti Putra Malaysia,
Selangor, Malaysia with the voucher specimen, No.
NL16, Bixa orellana. Leaves were then washed and
dried at 60 °C in an oven and powdered.
Preparation of plant extract
The plant extraction method was followed as reported
in a previous study [11]. Briefly, powdered leaves were
soaked in distilled water (1 g powder:20 ml distilled
water), and incubated in a water bath at 40 °C for 24 h.
The mixture was filtered and the filtrate was then
freeze-dried, yielding an aqueous extract (8.5 %. w/w).
Drugs and chemicals
Histamine, loratadine, fura-2-acetoxymethyl ester (FURA-
2 AM), verapamil, 2-aminoethoxydiphenyl borate (2-APB),
ethylene glycol tetraacetic acid (EGTA), Hank’s Balanced
Salt solution (HBSS), phosphate buffered saline (PBS) and
10× trypsin-EDTA solution were purchased from Signal
Chemical Co. Ltd. Malaysia. 1-[6-[[(17β)-3-methoxyes-
tra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-
dione (U-73122), L-NG-Nitroarginine methyl ester
hydrochloride (L-NAME), 6-(phenylamino)-5,8-quino-
linedione (LY 83583) and GF 109203X hydrochloride
were purchased from Merck, Malaysia.
Cell culture
HUVEC and growth medium (M200) supplemented with
a low-serum growth supplement were purchased from
Cascade Biologics (Portland). Cells were maintained at
37 °C in 5 % CO2 and 95 % ambient air in a humidified
cell culture incubator. Only cells from passages 1 to 5
were used in experiments. Cells were used for experi-
ments once they reached > 90 % confluence.
In vitro vascular permeability assay
The trans-endothelial flux of FITC-dextran across
cultured endothelial cell monolayers was measured
using a commercial in vitro vascular permeability
assay kit (Chemicon, International). Assay proce-
dures were slightly modified from the manufacturer’s
protocol. Briefly, cells were grown to confluence on
collagen-coated inserts. Cells were pre-treated with
AEBO at a concentration of 0.1–0.4 mg/ml for 12 h
and then challenged with histamine (100 μM),
followed by addition of FITC-dextran. The plate was
incubated for 5 min, and to stop the reaction, the
inserts were moved to another well for subsequent
time-point reading (15 and 30 min). Fluorescent
emissions were measured using a spectroflurometer
(Tecan) with a 485 and 530 nm filter set (Ex/Em).
Loratadine, an anti-histamine drug was used as a
positive control.
The permeability index (%) was calculated as:
experimental clearanceð Þ – spontaneous clearanceð Þ½ 
= clearance of the filter aloneð Þ – spontaneous clearance½ Þ x 100
Determination of Phospholipase C (PLC) activity
PLC activity was determined by quantification of inosi-
tol phosphate using a commercial IP-One ELISA kit
(Cisbio, USA) and the assay procedures were modified
from the manufacturer’s protocol. Cells were grown on
24-well plates and pretreated with AEBO at various
concentrations for 12 h before histamine was added.
1 h after exposure to histamine, cells were lysed and
centrifuged. Supernatants were transferred to a coated
ELISA plate and IP1-HRP conjugate and anti-IP1
monoclonal antibodies were added. The plate was incu-
bated for another 3 h, washed, and the reaction stopped
by addition of stop solution. The plate was read at
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450 nm with a wavelength correction at 620 nm
using a spectrophotometer (Tecan Infinite 200). The
concentration of inositol phosphate was calculated
from the standard curve, which was run together with
the samples. The PLC inhibitor, U-73122 was used as
a positive control.
Calcium signalling assay
Levels of intracellular calcium were measured in
HUVEC monolayers by Fura-2 AM ester modifed from
Grynkiewicz [14] following Chandra and Angle [15].
Briefly, cells were grown to confluence and pretreated
with AEBO at various concentrations. Cells were then
harvested with trypsin and washed with physiological
calcium-free HBSS, then centrifuged at 1000 rpm for
5 min. Next, cell pellets were incubated with Fura-1 AM
at a concentration of 2 μg/ml for 1 h at room
temperature covered with aluminium foil. Cells were
then washed with physiological calcium-free HBSS.
Aliquots of the Fura-2 AM-loaded cell suspension at a
concentration of 1 × 106 cells/ml were transferred to
glass cuvettes and stimulated with histamine only after
1 min of baseline recording. Readings from dual excita-
tion at 340/380 nm with an emission wavelength of
510 nm were recorded using a Perkin-Elmer Fluorescence
Spectrometer LS-55. Experiments were calibrated by the
addition of 2 % (w/v) Triton X-100, 5.2 mM MnCl2.4H2O
and 0.5 M EGTA. Changes in the level of intracellular
calcium ([Ca2+]i) were calculated by the calibration ratio
using the following equation:
Ca2þ
 
I ¼ k X R – Rminð Þ= Rmax– Rð Þ
Where R is the fluorescent measurement ratio (340/380),
Rmax is the ratio when the dye is saturated with cal-
cium obtained with 10 mM EGTA, Rmin is the ratio
with no free calcium present and k represents the
product of the effective dissociation constant for
Fura-2 AM and can be estimated from the calibration
curve for Fura-2 AM.
NO assay
Measurement of nitrite and nitrate as an indicator of
nitric oxide production was carried out using a nitrite/
nitrate assay kit (Roche, Malaysia). Briefly, cells were
pre-treated with AEBO before being challenged with his-
tamine. Samples were mixed with an equal volume of
Griess reagent. The nitrate in the samples was converted
to nitrite by adding nitrate reductase prior to Griess
reagent. L-NAME, an endothelial nitric oxide synthase
inhibitor was used as a positive control.
Determination of cyclic Guanosine Monophosphate
(cGMP) Production
Endothelial cGMP levels were quantified using a cGMP
enzyme immunoassay (R & D System, USA) according
to the manufacturer’s instructions. Cell culture superna-
tants were collected after cells were preincubated with
AEBO and then induced with histamine. Supernatants
were transferred onto an ELISA plate. The reaction was
stopped and measured by spectrophotometry at 450 nm
with a wavelength correction 570 nm within 30 min.
The mean absorbance was used to calculate cGMP con-
centration from the standard curve.
Quantification of Protein Kinase C (PKC) activity
PKC activity was determined using a commercial ELISA
kit (Enzo Life Sciences, Malaysia). Briefly, cell lysates
were prepared after 12 h of pretreatment with AEBO
and 30 min of stimulation with histamine. Cell lysates
were then transferred to an ELISA plate for the enzym-
atic reaction. The absorbance of the mixture in the plate
was then measured at 450 nm using a spectrophotom-
eter (Tecan, Infinite 200).
Statistical analysis
All values in the figures and test results are expressed as
mean ± SE. All experiments were performed in triplicate
with three independent tests. Statistical analysis of data
was performed by one-way analysis of variance (ANOVA)
and further analysed using Dunnet’s test. P values less
than 0.05 (p < 0.05) were considered significant.
Results
AEBO suppressed histamine-induced increased
endothelial permeability
In the current study, permeability of the HUVEC mono-
layer was measured three times at different time points
(i.e., 5, 15 and 30 min). Exposure of the monolayer to
histamine significantly increased HUVEC permeability
by approximately 5 to 6 fold, compared with baseline
(64.31 ± 3.08, 51.94 ± 1.17 and 56.44 ± 3.16 permeability
index of baseline at 5, 15 and 30 min, respectively;
Fig. 1). However, pre-incubation with AEBO at 0.1 and
0.2 mg/ml significantly reduced HUVEC hyperpermeabil-
ity caused by histamine at all time points and the highest
inhibitory effect was exhibited at the 15th min (i.e., 61.80
and 76.43 %, respectively). AEBO at 0.4 mg/ml demon-
strated the highest activity among all treatment groups
(88.34, 90.22 and 70.18 % at 5, 15 and 30 min, respect-
ively). The reference drug, Loratadine also showed a sig-
nificant reduction against histamine-induced increased
endothelial permeability. AEBO alone did not cause in-
creased endothelial permeability (data not shown), there-
fore, we concluded that this protective effect was specific
to injured endothelial cells.
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AEBO attenuated PLC activity
Quantification of inositol phosphate was used to indi-
cate PLC activity in the present study. As shown in
Fig. 2, stimulation of histamine led to a rise in the in-
ositol phosphate level, to approximately 70 ± 0.63 nM
higher than the basal level. Pre-treatment with AEBO
led to significant (p < 0.05) reductions in inositol
phosphate production in HUVEC in a dose-dependent
manner. Interestingly, a concentration of 0.4 mg/ml
showed maximal inhibition, with a 62.14 ± 1.82 nM
reduction of inositol phosphate production compared
with the negative control (90.01 % inhibition). To
confirm whether PLC signalling was involved in the
regulation of endothelial hyperpermeability, the effect
of the PLC inhibitor, U-73122 was measured. Pre-
treatment of HUVEC with U-73122 also successfully
suppressed histamine-induced inositol phosphate pro-
duction by approximately 41 ± 2.86 nM (60 %
Fig. 1 Effect of AEBO on histamine-induced increased HUVEC permeability for three different time points. Three independent experiments were
performed in triplicate. Data were expressed in mean ± SEM. *P < 0.05 considered significant versus control (histamine only) in each time point
Fig. 2 Effects of AEBO on histamine-induced production of inositol phosphate in cultured HUVEC. Three independent experiments were performed in
triplicate. Data were expressed in mean ± SEM. Data were analyzed by One-way ANOVA. *P < 0.05 (N = Treated with histamine only; P = Drug control,
10 μM of U-73122)
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inhibition) compared with the negative control. This
result suggested the involvement of PLC signalling in
the regulation of histamine-induced increased endo-
thelial permeability.
AEBO reduced histamine-induced calcium signalling
Inhibition of total calcium influx
In order to measure total calcium from both intracellu-
lar calcium release and extracellular calcium influx,
HBSS containing physiological calcium levels was used.
Total [Ca2+]i increased when HUVEC was induced with
histamine (Fig. 3a). However, HUVEC pre-incubated
with AEBO showed a reduction in total [Ca2+]i. AEBO
at 0.1 and 0.2 mg/ml suppressed total calcium influx by
up to 30.95 and 45.29 %, respectively. In addition,
0.4 mg/ml of AEBO possessed the highest inhibition ac-
tivity with approximately 67.94 %. The calcium channel
blocker, Verapamil, when used as a reference, showed
significant suppression of total [Ca2+]i.
Inhibition of intracellular calcium release
Intracellular calcium release was measured using the
same method as above, only the HBSS used was physio-
logically calcium free. As shown in Fig. 3b, exposure to
histamine induced a massive amount of [Ca2+]i release
from HUVEC. Pre-incubation of the HUVEC monolayer
with 0.1 and 0.2 mg/ml AEBO caused histamine to
induce the release of 76.28 ± 2.33 nM and 24.98 ± 3.65
nM of [Ca2+]i, respectively, while in the negative control,
103.75 ± 0.78 nM Ca2+ was released. The maximum
percentage of inhibition (90.80 %) was produced by the
highest dose of AEBO (0.4 mg/ml). This showed that the
effect of 0.4 mg/ml of AEBO was comparable to that of
the reference drug, 2-APB, which gave 89.63 %
Fig. 3 Effects of AEBO on histamine-induced [Ca2+]i in cultured HUVEC. Total calcium level was shown in 3(a), while intracellular calcium level
shown in 3(b). Three independent experiments were performed in triplicate. Data were expressed in mean ± SEM. Data were analyzed by One-way
ANOVA. *P < 0.05 significant different from negative control. [B = basal level; N = Treated with histamine only; P = Drug control, 10 μM of verapamil(3a)
and 2-APB(3b)]
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inhibition. Overall, our data suggested that the effect of
AEBO on histamine-induced endothelial hyperperme-
ability was, at least in part, mediated by the suppression
of intracellular calcium release.
AEBO decreased histamine-induced NO production
NO production was increased by histamine (100 μM)
from 8.65 ± 0.67 μM to 12.51 ± 0.88 μM, but was not sig-
nificantly suppressed by any concentration of AEBO
(Fig. 4). Only the highest dose of AEBO, 0.4 mg/ml, suc-
cessfully reduced the NO level induced by histamine in
HUVEC, with a percentage inhibition 51.66 %. However,
at two other concentrations, 0.1 and 0.2 mg/ml, AEBO
failed to reduce NO levels, and did not have a significant
effect on NO levels, compared with the negative control.
The association between reductions in NO levels and
endothelial hyperpermeability may indicate the mechan-
ism by which AEBO blocked the activation of PLC sig-
nalling and subsequently downregulated NO production.
AEBO abolished histamine-induced cGMP production
Histamine, at a concentration of 100 μM, increased
cGMP production up to three fold compared with basal
levels (1.55 ± 0.11 pmol/ml) (Fig. 5). AEBO at 0.1 mg/ml
did not have a significant effect on histamine-induced
cGMP production. However, 0.2 and 0.4 mg/ml of
AEBO notably reduced the levels of cGMP in HUVEC
when stimulated with histamine at 3.59 ± 0.11 pmol/ml
and 2.25 ± 0.12 pmol/ml, respectively. The maximal in-
hibitory rate (77.45 %) was found at 0.4 mg/ml of AEBO.
Overall, our data suggested that histamine-induced
endothelial hyperpermeability was involved in the
NO-cGMP signaling pathway; however, endothelial
hyperpermeability was abolished by pretreatment of
HUVEC with AEBO.
AEBO suppressed histamine-induced PKC activity in HUVEC
We wanted to know whether AEBO exerts its effect
on histamine-induced endothelial hyperpermeability
through the PKC pathway. To answer this question,
the effect of GF109203X hydrochloride, a specific in-
hibitor of PKC activity, on the levels of PKC protein in
histamine-treated HUVEC was measured by ELISA.
As shown in Fig. 6, stimulation of histamine led to up-
regulation of PKC activity in a HUVEC monolayer. All
of the AEBO concentrations ranging from 0.1 to
0.4 mg/ml showed significant reductions in PKC activ-
ity. The maximal inhibitory rate of 41.62 % was pro-
duced by 0.4 mg/ml of AEBO. Moreover, the positive
control also showed a significant difference, relative to
the negative control, with a percentage inhibition of
41.62 %. These data suggested that histamine-induced
endothelial hyperpermeability involved the activation
of PKC, which could be suppressed by AEBO.
Discussion
Previous studies have demonstrated anti-inflammatory
and antihistamine activities in aqueous extracts of B.
orellana (AEBO). These activities were implied by sup-
pression of vascular fluid extravasations induced by
histamine in animal model approaches [12]. Thus, ex-
tended works were carried out to elucidate its mechanism
of action against histamine-induced endothelial hyperper-
meability in vitro. The present study demonstrates that
Fig. 4 Evaluation of NO production by HUVEC stimulated with histamine which pre-treated by AEBO. Three independent experiments
were performed in triplicate. Data were expressed in mean ± SEM. *P < 0.05, significant different compared with the negative control
by One-way ANOVA, Post Hoc, Tukey test. (B = basal level; N = Treated with histamine only; P = Drug control, 10 μM of L-NAME)
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AEBO exhibits an anti-hyperpermeability effect induced
by histamine in human umbilical vein endothelial cells
(HUVEC). These activities are closely related to the sup-
pression of PLC-NO-cGMP signaling.
In order to show that AEBO were capable of producing
similar results as in an animal setting for the vascular per-
meability assay, an in vitro vascular permeability assay was
performed. In vitro studies of endothelial permeability that
have been used extensively and successfully are reported
in the literature [16–18]. The principle of the assay in-
volves the measurement of permeability of an endothelial
monolayer, assessed by the amount of dye that leaks
into the lower chamber from the upper chamber [16].
This assay is a good system for better understanding
the molecular mechanisms of human endothelial per-
meability. The current study demonstrated that AEBO
significantly suppressed histamine-induced endothelial
hyperpermeability and this effect was found to be
Fig. 5 Effect of AEBO on histamine-induced cGMP production in cultured HUVEC. Three independent experiments were performed in triplicate.
Data were expressed in mean ± SEM. Data were analyzed by One-way ANOVA. *P < 0.05 significant different from negative control. (B = basal level;
N = Treated with histamine only; P = Drug control, 10 μM of LY 83583)
Fig. 6 Effect of AEBO on histamine activated PKC activity (OD = optical density) in cultured HUVEC. Three independent experiments were
performed in triplicate. Data were expressed in mean ± SEM. Data were analyzed by One-way ANOVA. *P < 0.05 (B = basal level; N = Treated with
histamine only; P = Drug control, 10 μM of GF109203X hydrochloride)
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similar to that of the animal model reported previ-
ously. This confirms that AEBO exhibited a protective
effect on the endothelial barrier.
Next, our study attempted to elucidate the mechanism
of action of AEBO on the cellular and molecular levels.
Histamine, an endogenous inflammatory mediator, in-
creases endothelial permeability by binding to its recep-
tor, H1, a G-protein coupled receptor (GPCR) found on
endothelial cells [19]. A conformational change in the
GPCR leads to the activation of phospholipase C (PLC),
which catalyses the production of inositol triphosphate
(IP3) and diacylglycerol (DAG) [8, 20]. IP3 is then con-
verted to a more stable form, inositol monophosphate
(IP1). Due to the short of half-life of IP3, most assays in-
volve the use of radioisotopes, hence, for safety and
health concerns, the determination of IP1 levels was
chosen in the current study to indicate the activity of
PLC. Based on results that were obtained, pretreatment
of HUVEC with AEBO significantly reduced histamine-
stimulated PLC activity. This may indicate that AEBO
reduces endothelial hyperpermeability involved in sup-
pression of PLC activity. However, the effects of AEBO
on downstream signaling pathways remain unclear.
Thus, quantification of calcium signaling was per-
formed in the present study. Inositol phosphate, espe-
cially IP3, is an important second messenger that
induces the release of calcium from the endoplasmic
reticulum and the subsequent rise in intracellular cal-
cium [21]. Calcium is known to be an important key
regulator of a variety of cellular functions, including
the maintenance of endothelial cell integrity [22].
However, upregulation of intracellular calcium by in-
flammatory mediators leads to endothelial barrier dys-
function [23, 24]. In addition, recent findings have
suggested that calcium influx through cation channels
due to the depletion of intracellular calcium stores
plays an important role in increased endothelial per-
meability [25]. In the current study, calcium signalling
assays were performed in both the presence and ab-
sence of calcium. However, it appears that AEBO is
mainly involved in suppression of intracellular cal-
cium release, rather than extracellular calcium influx.
This suggests that AEBO may interfere with the
stimulation of membrane-bound enzyme complexes
such as PLC, thus reducing the production of by-
products, such as IP3 and DAG (Chandra and Angle [15]).
This eventually, leads to a decrease in intracellular calcium
release stimulated by IP3.
It is well established that the NO-cGMP signaling cas-
cade plays a key role in the regulation of endothelial per-
meability [26–28]. Numerous studies have shown that
increased endothelial permeability is caused by activa-
tion of the NO-cGMP signalling pathway [28, 29]. In
contrast, some studies demonstrated a barrier-enhancing
effect of cGMP [30, 31]. Different effects of NO and
cGMP on endothelial cells have been reported; this is
likely due to differences in experimental settings, such as
the species used, the particular vascular bed and the
physiological condition of the cells [32]. While upregula-
tion of NO-cGMP signalling induced by histamine in
HUVEC was showed in the current study, this condition
was abolished by preincubation with AEBO. Thus, the
current findings show that AEBO is capable of downreg-
ulating the NO-cGMP signaling pathway induced by
histamine in HUVEC.
Protein kinase C (PKC) activity is known to be acti-
vated by diacylglycerol (DAG), an end product of the
catalytic action of PLC [33]. In addition, Ca2+ signal-
ing pathways also enhance PKC activity [34]. As acti-
vation of PKC is involved in the phosphorylation of
cytoskeletal protein as well as in the reorganization of
intercellular junctions, it plays an important role in
the regulation of endothelial permeability [35]. Indeed,
upregulation of PKC activity in endothelial cells was
shown to increase endothelial cell permeability [36–38].
However, evidence also showed that the inhibition of PKC
activity led to a reduction in the effect of an agonist on
hyperpermeability [39]. The current study showed that
pre-treatment of AEBO on HUVEC slightly ameliorated
the PKC activity induced by an agonist. This suggests that
AEBO may be able to interfere with calcium signaling, but
fails to alter DAG signalling. However, further research is
needed in support of this hypothesis.
Conclusion
In conclusion, it was suggest that AEBO suppresses PLC
activity, which in turn leads to suppression of its down-
stream signalling pathway. This causes a reduction in
calcium concentration, nitric oxide and cGMP produc-
tion in cultured HUVEC when induced by histamine. In-
hibition of the PLC-NO-cGMP signalling pathway and
PKC activity by AEBO contributes to the suppression of
the increase in endothelial permeability, which may lead
to complicated illnesses.
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